Sep 2026
Abstract PR011: Digenic CRISPR screening identifies novel KRAS/FGFR combination therapies for pancreatic cancer
These findings establish RAS-pathway focused combinatorial CRISPR screening as a robust approach for identifying clinically actionable combination vulnerabilities and nominate FGFR signaling as a lineage-specific mediator of KRAS inhibitor resistance in PDAC.
R. Ebright, Yao He, Alan Zhang et al.
· Cancer Research · 0 citations